SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
slimchance
To: luckydog88 who wrote (63159)7/17/2025 9:57:51 AM
From: luckydog881 Recommendation   of 63281
 
and a third one came across the wires:

Baird analyst Brian Skorney maintains Sarepta Therapeutics(SRPT) with a Outperform and raises the price target from $30 to $35.

and saw this from Oppenheimer:

Elevidys, which treats the muscle-wasting disease called Duchenne muscular dystrophy, will remain on the market. But it will have a warning affixed to its label after two teens died of acute liver failure following treatment. Both boys were non-ambulatory, meaning they could no longer walk.

"We see this update as an important clearing event avoiding worst case scenario of ELEVIDYS being taken off the market," Oppenheimer analyst Andreas Argyrides said in a note to clients. "Current label continues to address the ambulatory population which represents a meaningful market opportunity."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News